Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
December 15 2022 - 7:48AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage biotechnology company specializing in the
development of AI-driven immunotherapies, today announced that
they expect to present data from their two clinical trials of
personalized cancer immunotherapies (cancer vaccines) EVX-01 and
EVX-02 in the second quarter of 2023.
By mid-2023, Evaxion will present the full clinical readout of
EVX-01 in metastatic melanoma and of EVX-02 in patients with
resected malignant melanoma. Both compounds are
neoantigen-targeting immunotherapies.
Evaxion has previously presented promising interim data for both
programs:
- EVX-01 Phase 1 interim data from 9 patients as previously
communicated here: High response rate to the combination treatment,
compared to historical data from studies where patients received
anti-PD1 treatment alone. The full readout will include results
from 13 patients with metastatic melanoma.
- EVX-02 Phase I/2a interim data from 8 patients as previously
communicated here: Robust and long-lasting CD4+ and CD8+ specific
T-cell responses in all patients, providing proof of mechanism for
the DNA-delivery technology. The full readout will include both
immune monitoring data and clinical outcome.
EVX-01 is currently in clinical Phase 2b in melanoma in
combination with Merck’s Keytruda®
Evaxion’s CEO Per Norlén comments: “We are thrilled about the
progress of our personalized cancer neoantigen programs, with
EVX-01 already in Phase 2b. The field is growing fast due to
positive clinical data and an increased number of high-profile
business deals. The emergence of more powerful AI and a new
generation of superior DNA and mRNA technologies have moved
personalized cancer immunotherapies from being an area of curiosity
to the next hot topic. With two programs in clinical Phases 1 and
2, a leading AI platform, and a next-generation DNA vaccine
technology, Evaxion is ready to lead the development of
next-generation cancer immunotherapies.”
Read more on clinicaltrials.gov: EVX-01 Ph1: NCT03715985, EVX-01
Ph2b: NCT05309421, EVX-02 Ph1/2a: NCT04455503.
About EvaxionEvaxion Biotech A/S is a clinical-stage biotech
company developing AI-powered immunotherapies. With our proprietary
and scalable AI technology, we decode the human immune system to
discover and develop novel immunotherapies for cancer, bacterial
diseases, and viral infections. Evaxion has a broad pipeline of
novel product candidates, including three personalized cancer
immunotherapies. It is located in Hørsholm, Denmark, with 70
employees.
For more information and please contact:CEO Per
Norlénpno@evaxion-biotech.com
Or: Katrine Hertz MortensenVP, Communications and Public
Relationskhm@evaxion-biotech.com+45 3010 0203
Source: Evaxion Biotech
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. The words “target,” “believe,”
“expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar
meaning identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work;
cost and success of our product development activities and
preclinical and clinical trials; commercializing any approved
pharmaceutical product developed using our AI platform technology,
including the rate and degree of market acceptance of our product
candidates; our dependence on third parties including for conduct
of clinical testing and product manufacture; our inability to enter
into partnerships; government regulation; protection of our
intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international
economic, political, legal, compliance, social and business
factors, including inflation, and the effects on our business
from the worldwide COVID-19 pandemic and the ongoing conflict in
the region surrounding Ukraine and Russia; and
other uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please
refer to the risk factors included in our most recent Annual Report
on Form 20-F and other filings with the U.S. Securities
and Exchange Commission (SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024